Provided By PR Newswire
Last update: Nov 14, 2023
INDIANAPOLIS, Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC") has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ: PNT) radioactive materials license (the "NRC Consent"), which will occur following the completion of Lilly's previously announced tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT, for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. Obtaining the NRC Consent is the last regulatory approval necessary for the consummation of the transaction.
Read more at prnewswire.com778.08
+7.44 (+0.97%)
Find more stocks in the Stock Screener
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Curious about the top performers within the S&P500 index in the middle of the day on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Friday to uncover the stocks that are gapping in the S&P500 index.
Wall Street stays cool despite geopolitical tension, weak retail data, and a meltdown in solar stocks.
Let's delve into the developments on the US markets one hour before the close of the markets on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.